返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular Attends Sixth Northwest Vascular Forum

[2017-05-16] 

Xi'an, China – From May 5 to May 6, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Northwest Vascular Forum & the 12th Chang'an Vascular Forum held in Xi'an and held a satellite meeting of "the Application of Unibody Stent Design in Endovascular Repair." Hosted by the First Affiliated Hospital of Xi'an Jiaotong University, the meeting invited several renowned vascular surgery specialists from China and abroad to share all-around the latest advancement and the development trend of the vascular surgery field in China.
 
During the satellite meeting of "the Application of Unibody Stent Design in Endovascular Repair," many specialists were invited for academic sharing. Professor Qingsheng Lu of Changhai Hospital of the Second Military Medical University delivered a speech of "the Distribution of Primary Tear in Aortic Arch and its Clinical Treatment Strategies" to share the treatment strategy of aortic arch and the design rationale of Castor™ Branched Aortic Stent-Graft System ("Castor™"). Professor Lu said, the hybrid surgery changes the morphology of the aortic arch and leads to large trauma. Its mid-term outcome is satisfactory but its long-term result remains uncertain and needs to be followed-up. In-situ fenestrated technique may result in brain ischemia and type III endoleak, and meanwhile due to the randomness of fenestration, its mid-term result is unknown. The chimney technique could lead to "gutter" endoleak due to the gutter between the branch stent graft and the main body. He pointed out, the unibody stent Castor™, jointly developed by MicroPort® Endovascular and Changhai Hospital of the Second Military Medical University, is the first stent system that reconstructs the descending aorta, aortic arch and great vessels of the arch all at once. The device features unique unibody structure – the branch and the main body is unified to avoid endoleak and long-term migration. In addition, it adopts standard design that takes a full consideration of the shape of the arch and the structure of the branch vessel. Also, the design of dual access introducing branch stent graft guarantees precise positioning of the main body and the branch, and the soft inner sheath makes the delivery faster and more precise.
 
Professor Hongyan Tian of the First Affiliated Hospital of Xi'an Jiaotong University, Professor Li Zhang of the Qinghai Cardiovascular Hospital, Professor Zhipeng Hu of the Cardia-cerebrovascular Disease Hospital of the General Hospital of Ningxia Medical University, Professor Quan Chen of the Gansu Provincial Hospital, and Professor Zhang Zhang of Tangdu Hospital of the Fourth Military Medical University also delivered speeches respectively regarding the clinical indications of the unibody bifurcated stent graft, the clinical experience of unibody bifurcated stent graft, as well as the clinical application of unibody bifurcated stent graft in EVAR and the treatment of abdominal aortic aneurysm. Their speeches fully explained the advantages of the unibody bifurcated stent graft in clinical application from different perspectives. They also had active interactions with the attendees about the key points of using the unibody stent.
 
As the world's first stent system that reconstructs the descending aorta, aortic arch and great vessels of the arch all at once, Castor™ represents the high-end unibody bifurcated stent graft. It was granted to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices, and is expected to be launched in China within this year. MicroPort® Endovascular President Zhenghua Miao said: "Castor™ provides a creative solution that makes the delivery and positioning of unibody branched stent much easier and features low occurrence of endoleak and good patency in branch vessel. Once launched, we believe it will provide ingenious, accurate and safe clinical experience for physicians and benefit more patients with aortic diseases as well."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® EP Obtains Thailand FDA Approval for Four Products
[Next]:MicroPort® Hosts the Fifth Science and Technology Conference